WO2012142615A3 - Auranofine et analogues d'auranofine utiles pour traiter une maladie proliférative et des troubles prolifératifs - Google Patents

Auranofine et analogues d'auranofine utiles pour traiter une maladie proliférative et des troubles prolifératifs Download PDF

Info

Publication number
WO2012142615A3
WO2012142615A3 PCT/US2012/033837 US2012033837W WO2012142615A3 WO 2012142615 A3 WO2012142615 A3 WO 2012142615A3 US 2012033837 W US2012033837 W US 2012033837W WO 2012142615 A3 WO2012142615 A3 WO 2012142615A3
Authority
WO
WIPO (PCT)
Prior art keywords
auranofin
disorders
treat proliferative
proliferative disease
compounds
Prior art date
Application number
PCT/US2012/033837
Other languages
English (en)
Other versions
WO2012142615A2 (fr
Inventor
Waldemar Priebe
Takayuki Kato
Izabela Fokt
Charles Conrad
Timothy Madden
Stanislaw Skora
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Publication of WO2012142615A2 publication Critical patent/WO2012142615A2/fr
Publication of WO2012142615A3 publication Critical patent/WO2012142615A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des analogues d'auranofine et des compositions pharmaceutiques qui inhibent le p-STAT3, conjointement avec des procédés de synthèse et des procédés d'utilisation des composés. L'invention concerne également des procédés de traitement de maladies et de troubles de p-STAT3 chez un patient en ayant besoin par administration d'une quantité thérapeutiquement efficace d'un ou plusieurs de ces composés, seuls ou en combinaison avec une autre thérapie médicamenteuse. Les composés et compositions pharmaceutiques selon l'invention sont utiles pour traiter des maladies prolifératives et troubles prolifératifs comprenant, mais sans y être limités, le cancer.
PCT/US2012/033837 2011-04-14 2012-04-16 Auranofine et analogues d'auranofine utiles pour traiter une maladie proliférative et des troubles prolifératifs WO2012142615A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161475600P 2011-04-14 2011-04-14
US61/475,600 2011-04-14

Publications (2)

Publication Number Publication Date
WO2012142615A2 WO2012142615A2 (fr) 2012-10-18
WO2012142615A3 true WO2012142615A3 (fr) 2013-01-31

Family

ID=47010040

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/033837 WO2012142615A2 (fr) 2011-04-14 2012-04-16 Auranofine et analogues d'auranofine utiles pour traiter une maladie proliférative et des troubles prolifératifs

Country Status (1)

Country Link
WO (1) WO2012142615A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2310020T (lt) 2008-07-11 2017-07-25 Board Of Regents, The University Of Texas System Nauji 2-deoksi monosacharidų acetatai, turintys priešvėžinį poveikį
EP2981270B1 (fr) 2013-04-05 2021-08-25 Board of Regents, The University of Texas System Esters de 2-désoxy-monosaccharides ayant une activité antiproliférative
WO2015127234A1 (fr) * 2014-02-20 2015-08-27 Board Of Regents, The University Of Texas System Utilisation d'ibrutinib pour le traitement du cancer à mutation de l'egfr
CN103980330B (zh) * 2014-04-04 2017-02-01 济南圣泉唐和唐生物科技有限公司 一种异硫脲氢溴酸盐的制备方法
CN107043404B (zh) * 2016-11-24 2020-08-11 中山大学肿瘤防治中心 新型膦金配合物及其抗肿瘤应用
SG11202110829YA (en) 2019-04-05 2021-10-28 Kymera Therapeutics Inc Stat degraders and uses thereof
CN112206238A (zh) * 2019-07-09 2021-01-12 厦门大学 金诺芬在肺癌治疗中的应用
AT523662B1 (de) 2020-03-16 2023-07-15 Aurovir Pharma Gmbh Gold-haltige Mittel zur Behandlung von Lungeninfektionen
WO2023242100A1 (fr) 2022-06-13 2023-12-21 KHR Biotec GmbH Nouveaux inhibiteurs de ras

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018598A2 (fr) * 2001-08-30 2003-03-06 University College Dublin Derives de monosaccharides
US20050043250A1 (en) * 2000-05-01 2005-02-24 Lampidis Theodore J. Cancer treatment including glycolytic inhibitors
US20050143336A1 (en) * 2003-12-30 2005-06-30 Board Of Regents, The University Of Texas System Methods and compositions for improved non-viral gene therapy
WO2010005799A2 (fr) * 2008-07-11 2010-01-14 Board Of Regents, The University Of Texas System Nouveaux acétates de 2-désoxy monosaccharides à activité anticancéreuse
US20100130434A1 (en) * 2006-02-24 2010-05-27 Board Of Regents, The University Of Texas System Hexose Compounds to Treat Cancer
US20110003758A1 (en) * 2006-04-27 2011-01-06 Waldemar Priebe Inhibitors of Glycolysis Useful In the Treatment of Brain Tumors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043250A1 (en) * 2000-05-01 2005-02-24 Lampidis Theodore J. Cancer treatment including glycolytic inhibitors
WO2003018598A2 (fr) * 2001-08-30 2003-03-06 University College Dublin Derives de monosaccharides
US20050143336A1 (en) * 2003-12-30 2005-06-30 Board Of Regents, The University Of Texas System Methods and compositions for improved non-viral gene therapy
US20100130434A1 (en) * 2006-02-24 2010-05-27 Board Of Regents, The University Of Texas System Hexose Compounds to Treat Cancer
US20110003758A1 (en) * 2006-04-27 2011-01-06 Waldemar Priebe Inhibitors of Glycolysis Useful In the Treatment of Brain Tumors
WO2010005799A2 (fr) * 2008-07-11 2010-01-14 Board Of Regents, The University Of Texas System Nouveaux acétates de 2-désoxy monosaccharides à activité anticancéreuse

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIM, N. H. ET AL.: "Auranofin blocks interleukin-6 signalling by inhibiting p hosphorylation of JAK1 and STAT3.", IMMUNOLOGY., vol. 122, no. 4, 2007, pages 6 07 - 614, XP055237295, DOI: doi:10.1111/j.1365-2567.2007.02679.x *

Also Published As

Publication number Publication date
WO2012142615A2 (fr) 2012-10-18

Similar Documents

Publication Publication Date Title
WO2012142615A3 (fr) Auranofine et analogues d'auranofine utiles pour traiter une maladie proliférative et des troubles prolifératifs
WO2013188847A8 (fr) Compositions et procédés pour l'absorption transmucosale
WO2011127333A3 (fr) Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques
WO2013158680A3 (fr) Compositions et méthodes comprenant du célécoxib ou composés apparentés et du dextrométhorphane
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
IN2012DN06720A (fr)
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
BR112015010396A2 (pt) terapia de combinação
MX2013012588A (es) Inhibidores de cinasa.
EA201171088A1 (ru) Лечение дискинезии при различных расстройствах
WO2016090024A3 (fr) Polythérapie pour le traitement du cancer
WO2012116176A3 (fr) Urées asymétriques et utilisations médicales de celles-ci
WO2014160216A3 (fr) Agents anticancéreux à double ciblage
WO2014078575A3 (fr) Nouveaux composés de modulation de régulation de la respiration oralement biodisponibles et leurs procédés d'utilisation
WO2013085849A3 (fr) Esters de sulfate de noribogaïne
WO2015009731A3 (fr) Analogues azacycliques de fty720 à structure contrainte
WO2014100679A8 (fr) Stimulation et augmentation de la régénération de tissus
WO2013173096A3 (fr) Conjugués d'huperzine et leurs analogues
BR112015007095A2 (pt) derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados
MX2014014817A (es) Compuestos para el tratamiento de inflamacion y dolor.
WO2013181217A3 (fr) Nouveaux composés et nouvelles compositions pour le traitement de troubles ou de maladies du contrôle de la respiration
MX2014011843A (es) Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma.
TW201613599A (en) Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease
MX2014000870A (es) Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12771343

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12771343

Country of ref document: EP

Kind code of ref document: A2